Abstract

Abstract The combination of gemcitabine and radiation is superior to gemcitabine alone for locally advanced pancreatic cancer however the median survival is only approximately one year. We have previously demonstrated that inhibition of Chk1 (checkpoint kinase 1) sensitizes pancreatic cancer cell lines, as well as patient-derived tumor xenografts, to both radiation and gemcitabine-radiation. The exact mechanism(s) for this sensitization, however, remains unclear. Based on the abilities of Chk1 to induce cell cycle arrest and promote HRR (homologous recombination repair) in response to DNA damage, we set out to determine the relevance of these mechanisms to radiosensitization by AZD7762, an AstraZenca Chk1/2 inhibitor currently in Phase I clinical trials. We tested the effects of AZD7762 on survival, cell cycle checkpoints, Rad51 focus formation and HRR activity in response to radiation and gemcitabine-radiation in two pancreatic cancer cell lines, Panc-1 and MiaPaCa-2. We began this study with the observation that AZD7762 sensitized MiaPaCa-2 cells to radiation and gemcitabine-radiation with enhancement ratios of 1.5 ± 0.08 (AZD7762), 1.2 ± 0.07 (50 nM gemcitabine), and 1.9 ± 0.16 (AZD7762 + 50 nM gemcitabine) but did not sensitize Panc-1 cells where enhancement ratios were 1.0 ± 0.03 (AZD7762), 1.5 ± 0.11 (100 nM gemcitabine), and 1.4 ± 0.05 (AZD7762 + 100 nM gemcitabine). AZD7762 inhibited Chk1 in both cell lines as evidenced by accumulation of Cdc25A and abrogation of the radiation-induced G2 arrest. To begin to determine the contribution of HRR to radiosensitization by AZD7762, we utilized a DR-GFP reporter assay which measures homology directed repair of an I-SceI endonuclease-induced DNA double strand break in an integrated GFP reporter gene in MiaPaCa-2 and Panc-1 cells. Treatment of cells expressing the DR-GFP reporter with 100 nM AZD7762 produced a 2- to 3-fold (P<0.05) inhibition of HRR activity in MiaPaCa-2 cells but minimal to no inhibition in Panc-1 cells. Inhibition of HRR by AZD7762 was accompanied by a reduction in the number of MiaPaCa-2 cells which stained positive for Rad51 foci in response to radiation (32 ± 3% versus 9 ± 3%; P<0.05). Taken together these results suggest that inhibition of HRR may play a role in the mechanism(s) of radiosensitization by Chk1 inhibition. It will be important in future studies to further decipher the contributions of cell cycle checkpoint abrogation and HRR inhibition to the mechanisms of radiosensitization by Chk1 inhibitors. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 491.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call